Oren Livnat
Stock Analyst at HC Wainwright & Co.
(4.54)
# 257
Out of 5,146 analysts
124
Total ratings
54.24%
Success rate
22.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $22.59 | +187.74% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $5.47 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $44.22 | +13.07% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $11.52 | +8.51% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $77.15 | +21.84% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $9.09 | +120.02% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $188.97 | +14.83% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $6.74 | +18.69% | 11 | Mar 7, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $75.87 | -3.78% | 9 | Feb 26, 2025 | |
| GRCE Grace Therapeutics | Reiterates: Buy | $12 | $4.12 | +191.26% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $3.24 | +131.48% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.71 | +1,034.75% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $10.00 | +495.00% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $0.59 | +33,250.18% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $22.59
Upside: +187.74%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.47
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $44.22
Upside: +13.07%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $11.52
Upside: +8.51%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $77.15
Upside: +21.84%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $9.09
Upside: +120.02%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $188.97
Upside: +14.83%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $6.74
Upside: +18.69%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $75.87
Upside: -3.78%
Grace Therapeutics
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $4.12
Upside: +191.26%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $3.24
Upside: +131.48%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.71
Upside: +1,034.75%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $10.00
Upside: +495.00%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $0.59
Upside: +33,250.18%